Ocular hypotensive effects of topically administered agmatine in a chronic ocular hypertensive rat model

Experimental Eye Research

Volumn 90, Issue 1, 2010, Pages 97-103

  Hong, Samin ^a   Kim, Chan Yun ^a   Lee, Won Seok ^a   Shim, Jongwoo ^a   Yeom, Ho Yeop ^b   Seong, Gong Je ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Siloan Eye Hospital   (South Korea)

Author keywords

agmatine; glaucoma; intraocular pressure; neuroprotection; retinal ganglion cell

Indexed keywords

AGMATINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CELL COUNT; CELL LABELING; CELL LOSS; CHRONIC DISEASE; CONTROLLED STUDY; DRUG EFFICACY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; AGMATINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL COUNT; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; INTRAOCULAR PRESSURE; MALE; NEUROPROTECTIVE AGENTS; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; RATS; RATS, SPRAGUE-DAWLEY; RETINAL GANGLION CELLS;

EID: 70749128761     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2009.09.016     Document Type: Article

References (58)

1. Ahmed F.A., Hegazy K., Chaudhary P., and Sharma S.C. Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. Brain Res. 913 (2001) 133-139
2. Bakalash S., Rolls A., Lider O., and Schwartz M. Chondroitin sulfate-derived disaccharide protects retinal cells from elevated intraocular pressure in aged and immunocompromised rats. Invest. Ophthalmol. Vis. Sci. 48 (2007) 1181-1190
3. Camras C.B., Schumer R.A., Marsk A., Lustgarten J.S., Serle J.B., Stjernschantz J., Bito L.Z., and Podos S.M. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch. Ophthalmol. 110 (1992) 1733-1738
4. Caprioli J. Correlation of visual function with optic nerve and nerve fiber layer structure in glaucoma. Surv. Ophthalmol. 33 (1989) S319-S330
5. Cornell Center for Animal Resources and Education. CARE101.01. Rodent Anesthesia. Standard Operating Procedures [serial Online]. Available from (2008), Cornell University, Ithaca, NY
6. Dudkowska M., Lai J., Gardini G., Stachurska A., Grzelakowska-Sztabert B., Colombatto S., and Manteuffel-Cymborowska M. Agmatine modulates the in vivo biosynthesis and interconversion of polyamines and cell proliferation. Biochim. Biophys. Acta 1619 (2003) 159-166
7. Fritzsch B. Fast axonal diffusion of 3000 molecular weight dextran amines. J. Neurosci. Methods 50 (1993) 95-103
8. Galea E., Regunathan S., Eliopoulos V., Feinstein D.L., and Reis D.J. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem. J. 316 (1996) 247-249
9. Gao H., Qiao X., Cantor L.B., and WuDunn D. Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch. Ophthalmol. 120 (2002) 797-803
10. García-Campos J., Villena A., Díaz F., Vidal L., Moreno M., and Pérez de Vargas I. Morphological and functional changes in experimental ocular hypertension and role of neuroprotective drugs. Histol. Histopathol 22 (2007) 1399-1411
11. Gilad G.M., and Gilad V.H. Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats. Neurosci. Lett. 296 (2000) 97-100
12. Gilad G.M., Salame K., Rabey J.M., and Gilad V.H. Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci. 58 (1996) PL41-PL46
13. Grillo M.A., and Colombatto S. Metabolism and function in animal tissues of agmatine, a biogenic amine formed from arginine. Amino Acids 26 (2004) 3-8
14. Halaris A., and Plietz J. Agmatine: metabolic pathway and spectrum of activity in brain. CNS Drugs 21 (2007) 885-900
15. Hare W., WoldeMussie E., Lai R., Ton H., Ruiz G., Feldmann B., Wijono M., Chun T., and Wheeler L. Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv. Ophthalmol. 45 (2001) S284-S289
16. Hartwick A.T. Beyond intraocular pressure: neuroprotective strategies for future glaucoma therapy. Optom. Vis. Sci. 78 (2001) 85-94
17. Heijl A., Leske M.C., Bengtsson B., Hyman L., Bengtsson B., Hussein M., and Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120 (2002) 1268-1279
18. Hong S., Kim C.Y., Lee J.E., and Seong G.J. Agmatine protects cultured retinal ganglion cells from tumor necrosis factor-alpha-induced apoptosis. Life Sci. 84 (2009) 28-32
19. Hong S., Lee J.E., Kim C.Y., and Seong G.J. Agmatine protects retinal ganglion cells from hypoxia-induced apoptosis in transformed rat retinal ganglion cell line. BMC Neurosci. 8 (2007) 81
20. Hong S., Park K., Kim C.Y., and Seong G.J. Agmatine inhibits hypoxia-induced TNF-alpha release from cultured retinal ganglion cells. Biocell 32 (2008) 201-205
21. Iizuka Y., Hong S., Kim C.Y., Kim S.K., and Seong G.J. Agmatine pretreatment protects retinal ganglion cells (RGC-5 cell line) from oxidative stress in vitro. Biocell 32 (2008) 245-250
22. Kalapesi F.B., Coroneo M.T., and Hill M.A. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br. J. Ophthalmol. 89 (2005) 758-763
23. Kalra S.P., Pearson E., Sahu A., and Kalra P.S. Agmatine, a novel hypothalamic amine, stimulates pituitary luteinizing hormone release in vivo and hypothalamic luteinizing hormone-releasing hormone release in vitro. Neurosci. Lett. 194 (1995) 165-168
24. Kanamori A., Nakamura M., Nakanishi Y., Yamada Y., and Negi A. Long-term glial reactivity in rat retinas ipsilateral and contralateral to experimental glaucoma. Exp. Eye Res. 81 (2005) 48-56
25. Kim J.H., Yenari M.A., Giffard R.G., Cho S.W., Park K.A., and Lee J.E. Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects cultured neurons from ischemia-like injury. Exp. Neurol. 189 (2004) 122-130
26. Kolesnikov Y., Jain S., and Pasternak G.W. Modulation of opioid analgesia by agmatine. Eur. J. Pharmacol. 296 (1996) 17-22
27. Kotil K., Kuscuoglu U., Kirali M., Uzun H., Akçetin M., and Bilge T. Investigation of the dose-dependent neuroprotective effects of agmatine in experimental spinal cord injury: a prospective randomized and placebo-control trial. J. Neurosurgery. Spine 4 (2006) 392-399
28. Li G., Regunathan S., Barrow C.J., Eshraghi J., Cooper R., and Reis D.J. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 263 (1994) 966-969
29. Mao L.K., Stewart W.C., and Shields M.B. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am. J. Ophthalmol. 111 (1991) 51-55
30. Mittag T.W., Danias J., Pohorenec G., Yuan H.M., Burakgazi E., Chalmers-Redman R., Podos S.M., and Tatton W.G. Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest. Ophthalmol. Vis. Sci. 41 (2000) 3451-3459
31. Nickells R.W. Apoptosis of retinal ganglion cells in glaucoma: an update of the molecular pathways involved in cell death. Surv. Ophthalmol. 43 (1999) S151-S161
32. Nissirios N., Chanis R., Johnson E., Morrison J., Cepurna W.O., Jia L., Mittag T., and Danias J. Comparison of anterior segment structures in two rat glaucoma models: an ultrasound biomicroscopic study. Invest. Ophthalmol. Vis. Sci. 49 (2008) 2478-2482
33. Olmos G., DeGregorio-Rocasolano N., Paz Regalado M., Gasull T., Assumpció Boronat M., Trullas R., Villarroel A., Lerma J., and García-Sevilla J.A. Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Br. J. Pharmacol. 127 (1999) 1317-1326
34. Quigley H.A. Neuronal death in glaucoma. Prog. Retin. Eye Res. 18 (1999) 39-57
35. Quigley H.A., and Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90 (2006) 262-267
36. Reis D.J., and Regunathan S. Is agmatine a novel neurotransmitter in brain?. Trends Pharmacol. Sci. 21 (2000) 187-193
37. Resnikoff S., Pascolini D., Etya'ale D., Kocur I., Pararajasegaram R., Pokharel G.P., and Mariotti S.P. Global data on visual impairment in the year 2002. Bull. World Health Organ 82 (2004) 844-851
38. Sawada A., and Neufeld A.H. Confirmation of the rat model of chronic, moderately elevated intraocular pressure. Exp. Eye Res. 69 (1999) 525-531
39. Sener A., Lebrun P., Blachier F., and Malaisse W.J. Stimulus-secretion coupling of arginine-induced insulin release. Insulinotropic action of agmatine. Biochem. Pharmacol. 38 (1989) 327-330
40. Serle J.B., Steidl S., Wang R.F., Mittag T.W., and Podos S.M. Selective alpha 2-adrenergic agonists B-HT 920 and UK14304-18. Effects on aqueous humor dynamics in monkeys. Arch. Ophthalmol. 109 (1991) 1158-1162
41. Shareef S.R., Garcia-Valenzuela E., Salierno A., Walsh J., and Sharma S.C. Chronic ocular hypertension following episcleral venous occlusion in rats. Exp. Eye Res. 61 (1995) 379-382
42. Sposato V., Iovieno A., Sornelli F., and Aloe L. Axonal transport deficit in the optic nerve of rats with inherited retinitis pigmentosa and experimentally induced glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 246 (2008) 1553-1558
43. Strutton D.R., and Walt J.G. Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J. Glaucoma 13 (2004) 221-226
44. Su R.B., Li J., and Qin B.Y. A biphasic opioid function modulator: agmatine. Acta Pharmacol. Sin 24 (2003) 631-636
45. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130 (2000) 429-440
46. Urcola J.H., Hernández M., and Vecino E. Three experimental glaucoma models in rats: comparison of the effects of intraocular pressure elevation on retinal ganglion cell size and death. Exp. Eye Res. 83 (2006) 429-437
47. van der Valk R., Schouten J.S., Webers C.A., Beckers H.J., van Amelsvoort L.G., Schouten H.J., Hendrikse F., and Prins M.H. The impact of a nationwide introduction of new drugs and a treatment protocol for glaucoma on the number of glaucoma surgeries. J. Glaucoma 14 (2005) 239-242
48. Vidal L., Díaz F., Villena A., Moreno M., Campos J.G., and de Vargas I.P. Nitric oxide synthase in retina and optic nerve head of rat with increased intraocular pressure and effect of timolol. Brain Res. Bull. 70 (2006) 406-413
49. Wang R.F., Serle J.B., Podos S.M., and Sugrue M.F. The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671,152 in glaucomatous monkeys. Arch. Ophthalmol. 108 (1990) 511-513
50. Wang W.P., Iyo A.H., Miguel-Hidalgo J., Regunathan S., and Zhu M.Y. Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. Brain Res. 1084 (2006) 210-216
51. Wheeler L.A., Gil D.W., and WoldeMussie E. Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv. Ophthalmol. 45 (2001) S290-S294
52. WoldeMussie E., Ruiz G., Wijono M., and Wheeler L.A. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest. Ophthalmol. Vis. Sci. 42 (2001) 2849-2855
53. Yoles E., Wheeler L.A., and Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest. Ophthalmol. Vis. Sci. 40 (1999) 65-73
54. Yu C.G., Marcillo A.E., Fairbanks C.A., Wilcox G.L., and Yezierski R.P. Agmatine improves locomotor function and reduces tissue damage following spinal cord injury. Neuroreport 11 (2000) 3203-3207
55. Yu S., Tanabe T., and Yoshimura N. A rat model of glaucoma induced by episcleral vein ligation. Exp. Eye Res. 83 (2006) 758-770
56. Zagon I.S., Klocek M.S., Sassani J.W., Mauger D.T., and McLaughlin P.J. Corneal safety of topically applied naltrexone. J. Ocul. Pharmacol. Ther. 22 (2006) 377-387
57. Zhu M.Y., Piletz J.E., Halaris A., and Regunathan S. Effect of agmatine against cell death induced by NMDA and glutamate in neurons and PC12 cells. Cell. Mol. Neurobiol. 23 (2003) 865-872
58. Zimmerman T.J., and Kaufman H.E. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch. Ophthalmol. 95 (1977) 601-604